Stephen J Crocker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9349930/publications.pdf

Version: 2024-02-01

66 papers	4,400 citations	126907 33 h-index	123424 61 g-index
68 all docs	68 docs citations	68 times ranked	5682 citing authors

#	Article	IF	Citations
1	Distinct profiles of cellular senescence-associated gene expression in the aged, diseased or injured central nervous system. Neuroscience Letters, 2022, 772, 136480.	2.1	0
2	The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease. ASN Neuro, 2022, 14, 175909142210878.	2.7	7
3	Therapeutic opportunities for targeting cellular senescence in progressive multiple sclerosis. Current Opinion in Pharmacology, 2022, 63, 102184.	3.5	2
4	Lipidomic analysis identifies age-disease-related changes and potential new biomarkers in brain-derived extracellular vesicles from metachromatic leukodystrophy mice. Lipids in Health and Disease, 2022, 21, 32.	3.0	5
5	The Cellular Senescence Factor Extracellular HMGB1 Directly Inhibits Oligodendrocyte Progenitor Cell Differentiation and Impairs CNS Remyelination. Frontiers in Cellular Neuroscience, 2022, 16, 833186.	3.7	7
6	‹scp›Cuprizoneâ€mediated‹/scp› demyelination reversibly degrades voiding behavior in mice while sparing brainstem reflex. Journal of Neuroscience Research, 2022, 100, 1707-1720.	2.9	2
7	Mesenchyme-specific loss of Dot1L histone methyltransferase leads to skeletal dysplasia phenotype in mice. Bone, 2021, 142, 115677.	2.9	7
8	Astrocyte-Derived Extracellular Vesicles (ADEVs): Deciphering their Influences in Aging. , 2021, 12, 1462.		11
9	Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease. Molecular Therapy, 2021, 29, 1883-1902.	8.2	22
10	Extracellular matrix influences astrocytic extracellular vesicle function in wound repair. Brain Research, 2021, 1763, 147462.	2.2	8
11	Targeted Complement Inhibition at Synapses Prevents Microglial Synaptic Engulfment and Synapse Loss in Demyelinating Disease. Immunity, 2020, 52, 167-182.e7.	14.3	244
12	The Effects of IL-1Î² on Astrocytes are Conveyed by Extracellular Vesicles and Influenced by Age. Neurochemical Research, 2020, 45, 694-707.	3.3	8
13	Stem Cells of the Aging Brain. Frontiers in Aging Neuroscience, 2020, 12, 247.	3.4	48
14	Astrocyte Support for Oligodendrocyte Differentiation can be Conveyed via Extracellular Vesicles but Diminishes with Age. Scientific Reports, 2020, 10, 828.	3.3	53
15	Effects of CNS Demyelination and Myelin Recovery on Urinary Physiology. Innovation in Aging, 2020, 4, 119-120.	0.1	0
16	TIMP-1 Promotes Oligodendrocyte Differentiation Through Receptor-Mediated Signaling. Molecular Neurobiology, 2019, 56, 3380-3392.	4.0	35
17	Systemic TLR2 tolerance enhances central nervous system remyelination. Journal of Neuroinflammation, 2019, 16, 158.	7.2	24
18	TIMP-1 Attenuates the Development of Inflammatory Pain Through MMP-Dependent and Receptor-Mediated Cell Signaling Mechanisms. Frontiers in Molecular Neuroscience, 2019, 12, 220.	2.9	50

#	Article	IF	Citations
19	Extracellular vesicle fibrinogen induces encephalitogenic CD8+ T cells in a mouse model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10488-10493.	7.1	54
20	Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9030-9039.	7.1	161
21	Long-Term Improvement of Neurological Signs and Metabolic Dysfunction in a Mouse Model of Krabbeâ€™s Disease after Global Gene Therapy. Molecular Therapy, 2018, 26, 874-889.	8.2	50
22	iPS-derived neural progenitor cells from PPMS patients reveal defect in myelin injury response. Experimental Neurology, 2017, 288, 114-121.	4.1	58
23	A Refined Bead-Free Method to Identify Astrocytic Exosomes in Primary Glial Cultures and Blood Plasma. Frontiers in Neuroscience, 2017, 11, 335.	2.8	29
24	The Mosaic of Extracellular Matrix in the Central Nervous System as a Determinant of Glial Heterogeneity. , 2016, , .		6
25	Transition from identity to bioactivityâ€guided proteomics for biomarker discovery with focus on the PF2D platform. Proteomics - Clinical Applications, 2016, 10, 8-24.	1.6	5
26	A microglial hypothesis of globoid cell leukodystrophy pathology. Journal of Neuroscience Research, 2016, 94, 1049-1061.	2.9	24
27	Extracellular matrix composition determines astrocyte responses to mechanical and inflammatory stimuli. Neuroscience Letters, 2015, 600, 104-109.	2.1	48
28	TIMP-1 couples RhoK activation to IL-1Î²-induced astrocyte responses. Neuroscience Letters, 2015, 609, 165-170.	2.1	12
29	Aberrant Production of Tenascin-C in Globoid Cell Leukodystrophy Alters Psychosine-Induced Microglial Functions. Journal of Neuropathology and Experimental Neurology, 2014, 73, 964-974.	1.7	30
30	Neuronal inclusions of Î±â€synuclein contribute to the pathogenesis of Krabbe disease. Journal of Pathology, 2014, 232, 509-521.	4.5	89
31	Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis. Stem Cell Reports, 2014, 3, 115-130.	4.8	140
32	An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy. Journal of Visualized Experiments, 2014, , e51903.	0.3	2
33	Astrocyte Regulation of CNS Inflammation and Remyelination. Brain Sciences, 2013, 3, 1109-1127.	2.3	66
34	MMPâ€3 mediates psychosineâ€induced globoid cell formation: Implications for leukodystrophy pathology. Glia, 2013, 61, 765-777.	4.9	33
35	An Alternate Perspective on the Roles of TIMPs and MMPs in Pathology. American Journal of Pathology, 2012, 180, 12-16.	3.8	168
36	Stomatin Inhibits Pannexin-1-Mediated Whole-Cell Currents by Interacting with Its Carboxyl Terminal. PLoS ONE, 2012, 7, e39489.	2.5	18

#	Article	IF	Citations
37	Intravenous administration of human embryonic stem cell-derived neural precursor cells attenuates cuprizone-induced central nervous system (CNS) demyelination. Neuropathology and Applied Neurobiology, 2011, 37, 643-653.	3.2	14
38	A dual role for microglia in promoting tissue inhibitor of metalloproteinase (TIMP) expression in glial cells in response to neuroinflammatory stimuli. Journal of Neuroinflammation, 2011, 8, 61.	7.2	35
39	How factors secreted from astrocytes impact myelin repair. Journal of Neuroscience Research, 2011, 89, 13-21.	2.9	139
40	Coxsackievirus Preferentially Replicates and Induces Cytopathic Effects in Undifferentiated Neural Progenitor Cells. Journal of Virology, 2011, 85, 5718-5732.	3.4	31
41	Astrocytic Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Promotes Oligodendrocyte Differentiation and Enhances CNS Myelination. Journal of Neuroscience, 2011, 31, 6247-6254.	3.6	101
42	Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis. Autophagy, 2009, 5, 152-158.	9.1	132
43	Viral Persistence and Chronic Immunopathology in the Adult Central Nervous System following Coxsackievirus Infection during the Neonatal Period. Journal of Virology, 2009, 83, 9356-9369.	3.4	76
44	Effects of calpain inhibition on dopaminergic markers and motor function following intrastriatal 6-hydroxydopamine administration in rats. Neuroscience, 2009, 158, 558-569.	2.3	20
45	A novel method to establish microgliaâ€free astrocyte cultures: Comparison of matrix metalloproteinase expression profiles in pure cultures of astrocytes and microglia. Glia, 2008, 56, 1187-1198.	4.9	73
46	Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. Multiple Sclerosis Journal, 2008, 14, 577-594.	3.0	34
47	Fibronectin- and Vitronectin-Induced Microglial Activation and Matrix Metalloproteinase-9 Expression Is Mediated by Integrins Î±5Î²1 and Î±vÎ²5. Journal of Immunology, 2007, 178, 8158-8167.	0.8	105
48	Amelioration of Coxsackievirus B3-Mediated Myocarditis by Inhibition of Tissue Inhibitors of Matrix Metalloproteinase-1. American Journal of Pathology, 2007, 171, 1762-1773.	3.8	35
49	Myelin oligodendrocyte glycoprotein peptide-induced experimental allergic encephalomyelitis and T cell responses are unaffected by immunoproteasome deficiency. Journal of Neuroimmunology, 2007, 192, 124-133.	2.3	14
50	Persistent Macrophage/Microglial Activation and Myelin Disruption after Experimental Autoimmune Encephalomyelitis in Tissue Inhibitor of Metalloproteinase-1-Deficient Mice. American Journal of Pathology, 2006, 169, 2104-2116.	3.8	85
51	Regulation of axotomy-induced dopaminergic neuron death and c-Jun phosphorylation by targeted inhibition of cdc42 or mixed lineage kinase. Journal of Neurochemistry, 2006, 96, 489-499.	3.9	13
52	Cell and agonist-specific regulation of genes for matrix metalloproteinases and their tissue inhibitors by primary glial cells. Journal of Neurochemistry, 2006, 98, 812-823.	3.9	55
53	Calpain Proteolysis and the Etiology of Parkinsonâ€™s Disease: An Emerging Hypothesis. , 2005, , 25-61.		1
54	Regulation of Dopaminergic Loss by Fas in a 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease. Journal of Neuroscience, 2004, 24, 2045-2053.	3.6	122

#	Article	IF	Citations
55	The TIMPs tango with MMPs and more in the central nervous system. Journal of Neuroscience Research, 2004, 75, 1-11.	2.9	121
56	BAG5 Inhibits Parkin and Enhances Dopaminergic Neuron Degeneration. Neuron, 2004, 44, 931-945.	8.1	199
57	Endogenous expression of inhibitor of apoptosis proteins in facial motoneurons of neonatal and adult rats following axotomy. Neuroscience, 2003, 117, 567-575.	2.3	11
58	Attenuation of MPTP-induced neurotoxicity and behavioural impairment in NSE-XIAP transgenic mice. Neurobiology of Disease, 2003, 12, 150-161.	4.4	55
59	Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13650-13655.	7.1	288
60	Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease. Journal of Neuroscience, 2003, 23, 4081-4091.	3.6	265
61	NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6â€OHDA rat model of Parkinson's disease. European Journal of Neuroscience, 2001, 14, 391-400.	2.6	72
62	c-Jun mediates axotomy-induced dopamine neuron death in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13385-13390.	7.1	84
63	Neuroprotection by the Inhibition of Apoptosis. Brain Pathology, 2000, 10, 283-292.	4.1	203
64	Attenuation of Ischemia-Induced Cellular and Behavioral Deficits by X Chromosome-Linked Inhibitor of Apoptosis Protein Overexpression in the Rat Hippocampus. Journal of Neuroscience, 1999, 19, 5026-5033.	3.6	199
65	D1-receptor-related priming is attenuated by antisense-meditated `knockdown' of fosB expression. Molecular Brain Research, 1998, 53, 69-77.	2.3	27
66	Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nature Medicine, 1997, 3, 997-1004.	30.7	257